Received Mar 25, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 2 | Unknown | PO / MO |
The patient received first dose of Vivotif on 01-Nov-2024, second dose on 03-Nov-2024, and third dose was missed; Case reference number US-BN-2024-002740 is a spontaneous case initially received from nurse via Med Communications (reference number: USBAV24-2924) on 06-Nov-2024 and concerns a patient of unknown age and gender. The patient's medical history and concomitant medication details were not provided. On 01-Nov-2024, at 7 pm, the patient took the first dose of Vivotif (batch number: unknown), at unknown dose, orally, for unknown indication. On 03-Nov-2024, two days after the first dose, at 7 pm, the patient took the second dose of Vivotif (batch number: unknown), at unknown dose, orally. On unspecified date, reported as last night at 7 pm, the patient missed the third dose of Vivotif vaccine (explicitly coded as 'missed dose'). At the time of the initial report, it was unknown if the patient experienced any adverse event due to Vivotif. Non-significant follow-up was downloaded from VAERS on 09-May-2025 included new reference number. Administrative update performed within the case: Worldwide Unique Case Identification Number (WWID) updated from US-20241106-97b5d1 to US-BAVARIAN NORDIC A/S-US-BN-2024-002740, in accordance with ICH guidance on WWID formatting.; Reporter's Comments: A patient of unknown age and gender missed the third dose of Vivotif vaccine which is considered as missed dose. Product dose omission issue is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse event due to Vivotif. The patient's medical history and concomitant medication details were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.; Sender's Comments: A patient of unknown age and gender missed the third dose of Vivotif vaccine which is considered as missed dose. Product dose omission issue is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse event due to Vivotif. The patient's medical history and concomitant medication details were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.
Comments: None.